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Abstract In this work, we explored the existence of genetic
variants within the apolipoprotein E gene transcriptional
regulatory region, using a denaturing gradient gel electrophoresis
screening of a region comprising nucleotides 31017 to +406.
Upon a population study, three new polymorphic sites (3491,
3427 and 3219) and two mutations were found. Functional
effects of the polymorphisms, assayed by transient transfection
and electrophoretic mobility shift assays in a human hepatoma
cell line, showed that polymorphisms at sites 3491 and 3219 of
the APOE promoter produce variations in the transcriptional
activity of the gene, most probably through differential binding of
nuclear proteins.
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1. Introduction
Apolipoprotein E (ApoE = protein; APOE = gene) is a
structural component of several lipoprotein species and plays
a central role in lipid metabolism through cellular uptake of
lipoprotein particles by lipoprotein receptors in the liver and
other tissues [1,2]. ApoE is a polymorphic protein, with three
common isoforms (ApoE2, ApoE3, and ApoE4), encoded by
three alleles (O2, O3, and O4) of a single gene on chromosome
19q13.2 [3]. This allelic variation contributes to susceptibility
to atherosclerotic cardiovascular disease [4] and Alzheimer’s
disease [5]. The APOE promoter region is very complex, host-
ing numerous regulatory elements located in the proximal 5P
£anking region and in the ¢rst intron of the human gene [6^9].
Thus, polymorphisms within this region could have functional
repercussions mediated by the regulation of APOE transcrip-
tion. To test this possibility, we have developed a method-
ology based on denaturing gradient gel electrophoresis
(DGGE), which allowed the screening of the 5P proximal re-
gion of the gene. Here we report the existence of three new
polymorphic sites in this region, two of which are associated
with di¡erential promoter activity and binding to nuclear pro-
teins in a human hepatoma cell line.
2. Materials and methods
For DGGE analysis, six overlapping fragments covering the region
from 31017 to +406 relative to the transcriptional start site [7] of the
APOE gene were obtained by PCR from genomic DNA and subjected
to DGGE followed by ethidium bromide staining. Parallel DGGE
experiments were performed as previously described [10,11] with mi-
nor modi¢cations. Brie£y, PCR products spanning nucleotides 31017
to 3717; 3786 to 3507; 3585 to 3285; 3363 to 3147; 3228 to
+154; and +93 to +406, and with a 40 bp GCclamp at one end were
subjected to DGGE using conditions speci¢c for each fragment (Bul-
lido et al., in preparation). PCR products showing abnormal migrat-
ing patterns were subjected to direct sequencing and analyzed in an
ALF DNA Sequencer (Pharmacia LKB).
Restriction fragment length polymorphism (RFLP) analysis of
3491A/T and 3427T/C polymorphisms was performed by digestion
of a PCR product spanning the region 3512 to 3285 with DraI and
AluI, respectively (primers: 5P-TGTTGGCCAGGCTGGTTTTAA-3P
(mismatched); 5P-CTTCCTTTCCTGACCCTGTCC-3P). For 3219G/
T polymorphism analysis, a PCR product spanning 3240 to 3147
was digested with TaqI (primers: 5P-CAGAATGGAGGAGGGTG-
TCTC-3P (mismatched) and 5P-GGAGGTGGGGCATAGAGGT-
CT-3P). The +113G/C polymorphism was analysed by NlaIV digestion
of a PCR product spanning +93 to +154 (primers: 5P-AA-
GAGCTGGGACCCTGGGAA-3P and 5P-CGACCCCGAGTAGCT-
CTCCTGA-3P). For ApoE genotyping, HhaI digestion of a 244 bp
PCR ampli¢ed fragment containing the two polymorphic sites of exon
4 of the APOE gene was performed as described [12].
Transient transfection of human hepatoma (HepG2) cells was per-
formed as described [9]. Brie£y, APOE region 31017 to +406 and
containing 3491A/3427T/3219T allelic form was ampli¢ed by PCR,
and site-directed mutagenesis was used to introduce the corresponding
mutations at positions 3491 (A to T), 3427 (T to C) or 3219 (T to
G). The constructs were cloned into the luciferase expression vector
pXP2 and transfected into HepG2 cells, together with a L-galactosid-
ase expression vector. Luciferase and L-galactosidase activities were
determined 2 days after transfection.
For electrophoretic mobility shift assays (EMSA), nuclear extracts
were prepared according to a described method [13]. Single stranded
oligonucleotides (5P-GCTGGTCTCAA(A/T)CTCCTGACCTTAA-3P,
5P-ACAGGCGTGAGC(T/C)ACCGCCCCCAGC-3P and 5P-GGAG-
GAGGGTGTCTG(T/G)ATTACTGGGCG-3P for 3491, 3427 and
3219 sites, respectively) were end-labeled with [Q-32P]ATP, annealed
to their complements and mixed with nuclear extracts in 15 mM Tris-
HCl pH 7.6 containing 15% glycerol, 50 mM NaCl, 3.75 mM MgCl2,
1.5 mM EDTA, 0.75 WM DTT and 0.1 Wg/Wl poly(dI-dC). Following a
20 min incubation at room temperature, the complexes were separated
in a 4% non-denaturing polyacrylamide gel, which was dried and
exposed to X-ray ¢lm.
3. Results and discussion
For the screening of polymorphisms in the APOE transcrip-
tional regulatory region, a set of PCR products spanning the
entire APOE promoter region (nucleotides from 31017 to
+406 relative to the transcriptional start site of the gene)
from 75 unrelated individuals were analyzed by DGGE. Frag-
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ments exhibiting altered migration patterns were subsequently
sequenced to determine the molecular nature of the variation.
We identi¢ed an A/T transversion at nucleotide 3491, a T/C
transition at nucleotide 3427, and a T/G transversion at nu-
cleotide 3219 (Fig. 1). A C/G transversion at nucleotide +113
in intron 1 was also found, as has been recently described [14].
Two C/T changes at nucleotides 3557 and 3456, respectively,
were also identi¢ed. No further variants were detected by
DGGE screening. To explore the possibility that polymor-
phisms not detected by DGGE might exist, we sequenced in
10 randomly chosen individuals the region 31017 to +406 of
the APOE gene. No polymorphisms were found other than
those shown in Fig. 1.
RFLP was used to determine the frequency of the APOE
promoter polymorphisms in a population of 215 healthy in-
dividuals aged 1^85 years. The genotype and allele frequencies
in this population are shown in Table 1A. The population was
also genotyped for the major APOE polymorphisms at exon 4
(Table 1B). The distribution of alleles into genotypes was
consistent with the Hardy-Weinberg equilibrium (M2 test,
Ps 0.2). Analysis of the allelic frequencies of each site be-
tween the genotypes corresponding to the rest of the polymor-
phic sites revealed a strong association between 3427C and
ApoE2 alleles (M2 test ; P = 1038) and between 3219G and
+113G alleles (P6 10310). According to previously reported
data [10], we found an increased frequency of +113G allele in
apoE4 individuals (M2 test; P = 0.003). No other signi¢cant
associations between APOE polymorphic sites were detected
in our population.
The e¡ect of polymorphism in the transcriptional activity of
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Fig. 1. Identi¢cation of polymorphic sites in the APOE promoter region. a: APOE gene scheme showing introns and 5P and 3P £anking regions
(line) and exons (hatched boxes, non-coding regions; full boxes, coding regions). b: APOE promoter region showing the sites where polymor-
phisms (double arrow) or mutations (single arrow) have been detected. c: Parallel DGGE analysis of APOE promoter region. A sample of a
heterozygous individual corresponding to each of the polymorphic sites is shown.
Table 1
APOE promoter genotype and allele distribution (A) and ApoE allele distribution (B)
Position Genotype Allele
A: APOE nucleotide
3557 CC CT TT C T
214 (0.99) 1 (6 0.01) 0 429 (0.99) 1 (6 0.01)
3491 AA AT TT A T
125 (0.58) 81 (0.38) 9 (0.04) 331 (0.77) 99 (0.23)
3456 CC CT TT C T
214 (0.99) 1 (6 0.01) 0 429 (0.99) 1 (6 0.01)
3427 TT TC CC T C
193 (0.90) 21 (0.10) 1 (6 0.01) 407 (0.95) 23 (0.05)
3219 GG GT TT G T
57 (0.28) 105 (0.51) 44 (0.21) 219 (0.53) 193 (0.47)
+113 GG GC CC G C
79 (0.37) 100 (0.47) 35 (0.16) 258 (0.60) 170 (0.40)
B: ApoE allele 4 3 2
34 (0.08) 372 (0.87) 24 (0.06)
Figures are numbers and, in parentheses, frequencies.
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APOE was analyzed by transient transfection assays. Since
the hepatocytes constitute the main cell type synthesizing
ApoE, the human cell line HepG2 (hepatoma) was used for
transfection. Taking as reference the activity of the construct
containing nucleotides 3491A, 3427T and 3219T, which cor-
responds to the ‘wild type’ haplotype, it was found that a
single A to T base substitution at nucleotide 3491 caused a
signi¢cant decrease in APOE promoter activity (63% of con-
trol, P = 0.002 by Student’s t-test), whereas a T to G substi-
tution at nucleotide 3219 provoked an increase in promoter
activity (169% of control, P = 0.001) (Fig. 2). By contrast, T to
C substitution at nucleotide 3427 had no signi¢cant e¡ect on
promoter activity in these cells. These results suggest that
sequences located around nucleotides 3491 and 3219 are in-
volved in the regulation of APOE transcription in hepatoma
cells.
In order to investigate if the di¡erential promoter activity
may be related to di¡erences in protein binding, EMSAs were
carried out using freshly prepared nuclear extracts from
HepG2 cells and oligonucleotide probes corresponding to
each of the allelic forms of the promoter. When the 3219
site was studied, a speci¢c band was detected which was
more intense with the 3219T probe than with the 3219G
probe (Fig. 3, arrow). A non-speci¢c band of higher mobility
was also observed (Fig. 3, asterisk). Similarly, we found a
di¡erential binding of oligonucleotides 3491A and 3491T
to HepG2 nuclear extracts (Bullido et al., Nature Genet., in
press). We were unable to detect di¡erences in the binding
pattern of nuclear proteins to the 3427T and 3427C probes
(not shown). The parallel behavior of the allelic forms in the
reporter gene expression and EMSA strongly suggests that
allelic di¡erences in APOE promoter activity in the hepatoma
cell line may be a consequence of di¡erential binding of nu-
clear proteins present in these cells.
It is well documented that single nucleotide changes within
a promoter region may dramatically a¡ect transcriptional ac-
tivity mediated by transcription factors [15,16], even when the
nucleotide change does not alter directly a DNA binding pro-
tein sequence motif and may be related to changes in the
secondary structure of DNA a¡ecting the access of transcrip-
tional factors [17]. Our ¢ndings identify an important source
of APOE gene diversity, and raise the possibility that such
regulatory region polymorphisms may confer in vivo allelic
di¡erences in expression, inducibility, and/or tissue speci¢city
of human APOE, and in the susceptibility to pathologies in
which ApoE is involved, such as atherosclerotic cardiovascu-
lar disease and Alzheimer’s disease. In this connection, we
have recently found that one of the polymorphisms described
here (3491A/T) is associated with an increased risk of AD
(Bullido et al., Nature Genet., in press).
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teins of APOE promoter. EMSA was performed using oligonucleo-
tide probes corresponding to 3491A/T and 3219T/G allelic forms
in the presence of HepG2 nuclear extracts. 32P-labeled probes were
incubated in the absence (3) or the presence (+) of nuclear extract
(N.E.). Competition experiments were performed by preincubating
the nuclear extract in the absence (3) or the presence of a 50-fold
excess (+) of unlabeled oligonucleotides, before addition of the
probes. Results shown are representative of at least four independ-
ent experiments.
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